Can we override clopidogrel resistance?

Circulation. 2009 Jun 2;119(21):2854-7. doi: 10.1161/CIRCULATIONAHA.108.857722.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / physiology
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Biotransformation / genetics
  • Clopidogrel
  • Combined Modality Therapy
  • Coronary Restenosis / diagnostic imaging
  • Coronary Restenosis / therapy*
  • Drug Resistance / genetics*
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / diagnostic imaging
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / therapy*
  • Piperazines / pharmacokinetics
  • Piperazines / therapeutic use*
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Polymorphism, Single Nucleotide*
  • Prasugrel Hydrochloride
  • Prodrugs / administration & dosage
  • Prodrugs / pharmacokinetics*
  • Prodrugs / therapeutic use
  • Radiography
  • Stents
  • Thiophenes / pharmacokinetics
  • Thiophenes / therapeutic use*
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics
  • Ticlopidine / therapeutic use

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Thiophenes
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • cytochrome P-450 CYP2D16 (guinea pig)
  • Prasugrel Hydrochloride
  • Ticlopidine
  • Aspirin